Beta Bionics CEO sells $113K in stock

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) reported that President & CEO Sean Saint sold 5,641 shares of common stock on September 3, 2026 at a weighted average price of $20.0778 per share, in an open-market transaction executed pursuant to a Rule 10b5-1 Plan adopted on September 5, 2025.

After this planned sale, he continued to hold 398,429 shares of Beta Bionics common stock directly.

Insider Trade Summary 10b5-1

Net Seller: 5,641 shares

Net Sell 1 txn

Insider Saint Sean

Role President & CEO

Sold 5,641 shs ($113K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	5,641	$20.0778	$113K

Holdings After Transaction: Common Stock — 398,429 shares (Direct)

Footnotes (2)

1. F1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 5, 2025.
2. F2. The weighted average sale price for the transaction reported was $20.0778 and the range of prices were between $20.00 and $20.1696. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 5,641 shares Weighted average sale price: $20.0778 per share Approximate transaction value: $113,258.87 +2 more

5 metrics

Shares sold 5,641 shares Common stock sold by President & CEO on September 3, 2026

Weighted average sale price $20.0778 per share Open-market sale of 5,641 BBNX shares

Approximate transaction value $113,258.87 5,641 shares sold at a weighted average price of $20.0778

Shares held after transaction 398,429 shares Direct ownership by President & CEO following the sale

Rule 10b5-1 plan adoption date September 5, 2025 Plan under which the September 3, 2026 sale was executed

Key Terms

Rule 10b5-1 Plan, weighted average sale price, open market

3 terms

Rule 10b5-1 Plan regulatory

"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 5, 2025"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $20.0778"

open market market

"Sale in open market or private transaction"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

FAQ

What insider transaction did BBNX report in this Form 4?

BBNX reported that President & CEO Sean Saint sold 5,641 shares of common stock on September 3, 2026 in an open-market transaction at a weighted average price of $20.0778 per share, under a pre-arranged Rule 10b5-1 trading plan.

How many BBNX shares does the CEO hold after this transaction?

After the reported sale, President & CEO Sean Saint directly held 398,429 shares of Beta Bionics, Inc. common stock, as disclosed in the Form 4 filing.

Was the BBNX CEO’s stock sale made under a Rule 10b5-1 plan?

Yes. The filing states the shares were sold pursuant to a Rule 10b5-1 Plan that was adopted on September 5, 2025, indicating the trades were pre-arranged rather than initiated at the time of sale.

What price range did the BBNX CEO’s share sales occur at?

The filing reports a weighted average sale price of $20.0778 per share, with individual sale prices ranging between $20.00 and $20.1696 for the 5,641 shares sold.

What was the approximate dollar value of the BBNX CEO’s share sale?

Based on 5,641 shares sold at a weighted average price of $20.0778 per share, the transaction totaled approximately $113,258.87 in sale proceeds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 05:19 PM Accepted by SEC EDGAR 09/04/2026 - 05:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saint Sean

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2026		S(1)		5,641	D	$20.0778(2)	398,429	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 5, 2025.

2. The weighted average sale price for the transaction reported was $20.0778 and the range of prices were between $20.00 and $20.1696. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Stephen Feider, Attorney-in-Fact	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)